How biologic agents revolutionised IBD management

Treatment goals are no longer limited to symptom control

Over the past two decades, biologic agents have transformed the inflammatory bowel disease (IBD) therapeutic landscape.

These relatively new medications have contributed to significant improvements in patient outcomes, and shifted the goals of therapy from short-term symptomatic control to long-term alteration of disease course and complications.

Anti-tumour necrosis factor (TNF) therapies

This class of therapy has revolutionised the treatment of IBD in recent years, particularly in conditions for which